Literature DB >> 1681997

Dopaminergic and noradrenergic modulation of amphetamine-induced changes in auditory gating.

K E Stevens1, L L Fuller, G M Rose.   

Abstract

Dopaminergic and noradrenergic mediation of central sensory gating were assessed in Sprague-Dawley rats using a condition-test paradigm in which auditory evoked potentials were recorded. In this paradigm, unmedicated rats 'gate', i.e. suppress the response to the second of a pair of clicks delivered at a 0.5 s interval. Amphetamine-treated rats fail to gate; in this respect, they resemble schizophrenic humans. Previous studies had indicated noradrenergic involvement in the mediation of auditory gating in rats. In this study, we used selective antagonists to assess the contribution of alpha- and beta-adrenergic receptors, and dopamine D1- and D2-receptors, to amphetamine-induced alterations in gating. Both the alpha-antagonist, phentolamine, and the beta-antagonist, timolol, normalized gating by potentiating amphetamine-induced decreases in the amplitude of the test response. SCH 23390, a D1-receptor antagonist, also normalized gating, but by elevating the amphetamine-reduced amplitude of the conditioning response. Sulpiride did not significantly alter amphetamine-induced changes in gating. Thus, both noradrenergic alpha- and beta-receptors and dopamine D1-receptors appear to modulate gating. However, their dissimilar means of normalizing gating suggests that noradrenergic and dopaminergic drugs act via different mechanisms and possibly different neuroanatomical loci.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1681997     DOI: 10.1016/0006-8993(91)90864-r

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  18 in total

1.  Differential effects of estrogen and testosterone on auditory sensory gating in rats.

Authors:  Shane J Thwaites; Maarten van den Buuse; Andrea Gogos
Journal:  Psychopharmacology (Berl)       Date:  2013-08-09       Impact factor: 4.530

2.  Sensory and sensorimotor gating-disruptive effects of apomorphine in Sprague Dawley and Long Evans rats.

Authors:  Michelle R Breier; Brittanni Lewis; Jody M Shoemaker; Gregory A Light; Neal R Swerdlow
Journal:  Behav Brain Res       Date:  2010-01-18       Impact factor: 3.332

3.  Stimulation of the alpha4beta2 nicotinic receptor by 5-I A-85380 improves auditory gating in DBA/2 mice.

Authors:  Kristin M Wildeboer; Karen E Stevens
Journal:  Brain Res       Date:  2008-06-11       Impact factor: 3.252

4.  Effects of acute and chronic clozapine on D-amphetamine-induced disruption of auditory gating in the rat.

Authors:  Brian Joy; Robert P McMahon; Paul D Shepard
Journal:  Psychopharmacology (Berl)       Date:  2004-07       Impact factor: 4.530

Review 5.  Pre-attentive processing and schizophrenia: animal studies.

Authors:  Bart A Ellenbroek
Journal:  Psychopharmacology (Berl)       Date:  2003-12-04       Impact factor: 4.530

6.  Olanzapine improves deficient sensory inhibition in DBA/2 mice.

Authors:  Johanna K Simosky; Robert Freedman; Karen E Stevens
Journal:  Brain Res       Date:  2008-07-25       Impact factor: 3.252

7.  Permanent improvement in deficient sensory inhibition in DBA/2 mice with increased perinatal choline.

Authors:  Karen E Stevens; Catherine E Adams; Joan Yonchek; Cindy Hickel; Jeffrey Danielson; Michael A Kisley
Journal:  Psychopharmacology (Berl)       Date:  2008-04-30       Impact factor: 4.530

8.  DMXB, an alpha7 nicotinic agonist, normalizes auditory gating in isolation-reared rats.

Authors:  Heidi C O'Neill; Kate Rieger; William R Kem; Karen E Stevens
Journal:  Psychopharmacology (Berl)       Date:  2003-05-21       Impact factor: 4.530

9.  Animal Models of Psychosis: Current State and Future Directions.

Authors:  Alexandra D Forrest; Carlos A Coto; Steven J Siegel
Journal:  Curr Behav Neurosci Rep       Date:  2014-06-01

10.  Auditory sensory gating in the neonatal ventral hippocampal lesion model of schizophrenia.

Authors:  Jenifer L Vohs; R Andrew Chambers; Giri P Krishnan; Brian F O'Donnell; William P Hetrick; Samuel T Kaiser; Sarah Berg; Sandra L Morzorati
Journal:  Neuropsychobiology       Date:  2009-08-14       Impact factor: 2.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.